Interní Med. 2017; 19(5): 246-250 | DOI: 10.36290/int.2017.040

Commentary on the new guidelines for endocrine orbitopathy

MUDr. Jan Schovánek, Ph.D.¹, MUDr. Ľubica Cibičková, Ph.D.¹, MUDr. Marta Karhanová, Ph.D., FEBO², MUDr. Jana Kalitová², doc. MUDr. Zdeněk Fryšák, CSc.¹, doc. MUDr. David Karásek, Ph.D.¹

III. interní klinika – nefrologická, revmatologická a endokrinologická, Fakultní nemocnice Olomouc

¹ a Lékařská fakulta Univerzity Palackého v Olomouci, Olomouc

² Oční klinika, Fakultní nemocnice Olomouc a Lékařská fakulta Univerzity Palackého v Olomouci, Olomouc

Endocrine or Graves-Basedow Orbitopathy (EO) is a serious, progressive ocular complication associated with autoimmune thyroiddisease. Typical symptoms include upper eyelid retraction, periorbital edema, bulb disorder, diplopia, inflammation of the orbitalsoft tissue leading to the eye-ball protrusion and in more serious cases, loss of vision due to optic nerve suppression or cornealdamage. The standard of treatment is corticotherapy, the administration of per os is limited by the side effects, therefore intravenouspulses are preferred. In 2016, a single recommendation was issued by the European Thyroid Association and the EuropeanGroup on Graves Orbithopathies (EUGOGO) for Endocrine Orbitopathy, as well as the recommendations of the American ThyroidAssociation for the Treatment of Hyperthyroidism, which mentions the treatment of EO.

Keywords: endocrine orbitopathy, corticosteroids, rituximab, guidelines

Published: December 1, 2017  Show citation